Challenges of drug discovery for personalized medicine

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 6, 2006, Pages 487-492

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Biomarkers; Cytomics; Drug discovery; Nanobiotechnology; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Pharmacometabolomics; Pharmacoproteomics; RNA interference

Indexed keywords

APOLIPOPROTEIN E; BETA 2 ADRENERGIC RECEPTOR; BIOLOGICAL MARKER; CANCER VACCINE; PARACETAMOL; VACCINE;

ALZHEIMER DISEASE; BIOTECHNOLOGY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL FUNCTION; DISEASE COURSE; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; DRUG URINE LEVEL; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE INTERACTION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; GENETIC CODE; GENETIC DISORDER; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER INJURY; METABOLOMICS; NANOCRYSTAL; NANOPARTICLE; NANOTECHNOLOGY; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEIN POLYMORPHISM; PROTEOMICS; RACE DIFFERENCE; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; CANCER VACCINES; DRUG DESIGN; DRUG INDUSTRY; DRUG THERAPY; EPIGENESIS, GENETIC; HUMANS; NANOTECHNOLOGY; NEOPLASMS; PHARMACOGENETICS; PROTEOMICS; RNA INTERFERENCE; SYSTEMS BIOLOGY;

EID: 33845524213     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Jain KK: Personalized Madicine: Scientific & Commercial Aspects. Jain PharmaBiotech Publications, Basel, Switzerland (2006).
2. Roses AD, Burns DK, Chissoe S, Middleton L, St Jean P: Disease-specific target selection: A critical first stop down the right road. Drug Disc Today (2005) 10(3):177-189.
3. Penny MA, McHale D: Pharmacogenomics and the drug discovery pipeline: When should it be implemented? Am J Pharmacogenomics (2005) 6(1):53-62.
4. Wilkinson GR: Drug metabolism and variability among patients in drug response. N Engl J Med (2005) 352(21):2211-2221.
5. Kennedy S: The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers (2002) 7(4):269-290.
6. Jain KK: RNAI and sIRNA. Pharmacogenomics (2004) 6(3):239-242.
7. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK: Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature (2006) 440(7087):1073-1077.
8. Haselden JN, Nicholls AW: Personalized medicine progresses. Nat Med (2008) 12(5):510-511.
9. Jain KK: Cytogenetics. Technologies, Markets and Companies. Jain PharmaBiotech Publications, Basel, Switzerland (2006):145.
10. Valet G: Cytomics, the human cytome project and systems biology. Top-down resolution of the molecular biocomplexity of organisms by single cell analysis. Cell Prolif (2005) 38(4):171-174.
11. Valet G: Cytomics as a new potential for drug discovery. Drug Disc Today (2008) 11(17-18):785-791.
12. Jain KK: Biomarkers: Technologies, Markets and Companies. Jain PharmaBiotech Publications, Basel, Switzerland (2008):582.
13. Jain KK: The role of nanobiotechnology in drug discovery. Drug Disc Today (2005) 10(21):1435-1442.
14. Volt E, Neves AR, Santos H: The intricate side of systems biology. Proc Natl Acad Sci USA (2008) 103(25):9452-9457.
15. Butcher EC: Can cell systems biology rescue drug discovery? Nat Rev Drug Discov (2005) 4(6):461-467.
16. Jain KK: Personalised medicine for cancer: From drug development into clinical practice. Exp Opin Pharmacother (2005) 6(9):1463-1476.
17. Itoh K, Yamada A: Personalized peptide vaccines: A new therapeutic modality for cancer. Cancer Sci (2006) 97(10):970-976.
18. Balch C, Montgomery JS, Paik HI, Kim S, Kim S, Huang TH, Nephew KP: New anti-cancer strategies: Epigenetic therapies and biomarkers. Front Biosci (2005) 10(2):1897-1931.
19. Esteller M: DNA methylation and cancer therapy: New developments and expectations. Curr Opin Oncol (2005) 17(1):55-60.
20. Jain KK: Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics (2004) 1(1):49-55.
21. Stoughton RB, Friend SH: How molecular profiling could revolutionize drug discovery. Nat Rev Drug Discov (2005) 4(4):345-350.